Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | SELL | P14151 | 1/20 | 0.44 |
| ▸ | SELP | P16109 | 1/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.44 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 4/20 | 0.39 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.39 |
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL137360 | 0.88 | ALDH1A1 (0.43) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL137326 | 0.85 | UCHL1 (0.47) | GAAALDH1A1UCHL1L3MBTL1LMNA | |
| SCHEMBL2725415 | 0.83 | TTR (0.41) | ALDH1A1TSHRNFKB1UCHL1HTT | |
| SCHEMBL27875445 | 0.82 | SLC22A12 (0.44) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL3551522 | 0.81 | LPL (0.41) | GAAALDH1A1UCHL1HTTLMNA | |
| SCHEMBL28722188 | 0.81 | TPH1 (0.47) | ALDH1A1TDP1PTGS1HSD17B10LDHA | |
| SCHEMBL3476855 | 0.81 | GAA (0.39) | GAAALDH1A1TSHRNFKB1TDP1 | |
| SCHEMBL17364642 | 0.81 | LPL (0.39) | TSHRNFKB1UCHL1LMNALIPG | |
| SCHEMBL1445630 | 0.81 | PDE4D (0.43) | ALDH1A1UCHL1LIPG | |
| SCHEMBL30526866 | 0.80 | LPL (0.37) | GAAALDH1A1UCHL1LMNALIPG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2855483-B1 | PYRROLOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2017-10-25 | — | — | EP | disclosed |
| EP-2632269-B1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONES AS CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2017-03-15 | — | — | EP | disclosed |
| US-9365576-B2 | Pyrrolopyrrolidinone compounds | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| US-9365576-B2 | Pyrrolopyrrolidinone compounds | NOVARTIS AG (CH) | 2016-06-14 | — | — | US | disclosed |
| US-9221834-B2 | Cyclic amine substituted oxazolidinone CETP inhibitor | MERCK SHARP & DOHME CORP. (US) | 2015-12-29 | — | — | US | disclosed |
| EP-2855483-A1 | PYRROLOPYRROLIDINONE COMPOUNDS | Novartis AG (CH) | 2015-04-08 | — | — | EP | disclosed |
| US-20130331372-A1 | Cyclic Amine Substituted Oxazolidinone CETP Inhibitor | MERCK SHARP & DOHME CORP. | 2013-12-12 | — | — | US | disclosed |
| WO-2013175417-A1 | PYRROLOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2013-11-28 | — | — | WO | disclosed |
| WO-2013175417-A1 | PYRROLOPYRROLIDINONE COMPOUNDS | NOVARTIS AG (CH) | 2013-11-28 | — | — | WO | disclosed |
| EP-1971595-B1 | CETP INHIBITORS | MERCK SHARP & DOHME (US) | 2013-10-16 | — | — | EP | disclosed |
| EP-2632269-A1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONE CETP INHIBITOR | Merck Sharp & Dohme Corp. (US) | 2013-09-04 | — | — | EP | disclosed |
| WO-2012058187-A1 | CYCLIC AMINE SUBSTITUTED OXAZOLIDINONE CETP INHIBITOR | MERCK SHARP & DOHME CORP. (US) | 2012-05-03 | — | — | WO | disclosed |
| US-20090042892-A1 | Cetp Inhibitors | MERCK SHARP & DOHME LLC | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042892-A1 | Cetp Inhibitors | CETP, APOB, MTTP | GAA 1668/4885ALDH1A1 3603/4885TSHR 3089/4885 |
| US-20130331372-A1 | Cyclic Amine Substituted Oxazolidinone CETP Inhibitor | CETP, APOB, MTTP | GAA 3217/4885ALDH1A1 2647/4885TSHR 3756/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.